



## **RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022**

March 9, 2022

BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2022, as follows:

Date: Wednesday, March 16, 2022  
Time: 11:15 a.m. ET  
Webcast: [https://cc.webcasts.com/barc002/031522a\\_js/?entity=85\\_1GFQ11B](https://cc.webcasts.com/barc002/031522a_js/?entity=85_1GFQ11B)

The webcast will be available thereafter via the Company's website [www.rvlpharma.com](http://www.rvlpharma.com) website under the "Investor & News" section.

### **About RVL Pharmaceuticals plc**

RVL Pharmaceuticals plc (Nasdaq: RVLP) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc., is the Company's ophthalmic and medical aesthetics subsidiary supporting UPNEEQ®.

### **Investor and Media Relations for RVL Pharmaceuticals plc**

Lisa M. Wilson  
In-Site Communications, Inc.  
T: 212-452-2793  
E: [lwilson@insitecony.com](mailto:lwilson@insitecony.com)